An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

Wilms’ tumor 1 (WT1) is a promising tumor-associated antigen for cancer immunotherapy. We developed an oral protein vaccine platform composed of WT1-anchored, genetically engineered Bifidobacterium longum ( B. longum ) and conducted an in vivo study in mice to examine its anticancer activity. Mice were orally treated with phosphate-buffered saline, wild-type B. longum 105-A, B. longum 2012 displaying only galacto-N-biose/lacto-N-biose I-binding protein (GLBP), and WT1 protein- and GLBP-expressing B. longum 420. Tumor size reduced significantly in the B. longum 420 group than in the B. longum 105-A and 2012 groups ( P < 0.00 l each), indicating B. longum 420’s antitumor activity via WT1-specific immune responses. CD8 + T cells played a major role in the antitumor activity of B. longum 420. The proportion of CD103 + CD11b + CD11c + dendritic cells (DCs) increased in the Peyer’s patches (PPs) from mice in the B. longum 420 group, indicating the definite activation of DCs. In the PPs, the number and proportion of CD8 + T cells capable of producing interferon-gamma were significantly greater in the B. longum 420 group than in the B. longum 2012 group ( P < 0.05 or < 0.01). The production of WT1-specific IgG antibody was significantly higher in the B. longum 420 group than in the 2012 group ( P < 0.05). The B. longum 420 group showed the most intense intratumoral infiltration of CD4 + and CD8 + T cells primed by activated DCs in the PPs of mice in the B. longum 420 group. Our findings provide insights into a novel, intestinal bacterium-based, cancer immunotherapy through intestinal immunity.